Immutep Ltd ADR - Asset Resilience Ratio
Immutep Ltd ADR (IMMP) has an Asset Resilience Ratio of 17.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMMP working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Immutep Ltd ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Immutep Ltd ADR's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Immutep Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Immutep Ltd ADR carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $26.38 Million | 17.92% |
| Total Liquid Assets | $26.38 Million | 17.92% |
Asset Resilience Insights
- Good Liquidity Position: Immutep Ltd ADR maintains a healthy 17.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Immutep Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Immutep Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Immutep Ltd ADR (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Immutep Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 39.68% | $62.28 Million | $156.98 Million | +29.71pp |
| 2024-06-30 | 9.96% | $20.09 Million | $201.58 Million | -- |
| 2023-06-30 | 0.00% | $0.00 | $147.45 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $40.54 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $47.00 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $34.96 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $42.55 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $30.98 Million | -- |
| 2014-06-30 | 35.46% | $9.00 Million | $25.38 Million | +11.08pp |
| 2013-06-30 | 24.38% | $8.00 Million | $32.81 Million | -26.19pp |
| 2012-06-30 | 50.57% | $21.05 Million | $41.61 Million | +33.23pp |
| 2011-06-30 | 17.35% | $10.00 Million | $57.64 Million | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more